|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
SundayPress Release: Surveyed U.S. Neurologists Would be Willing to Accept a Novel Primary-Progressive MS
BURLINGTON, Mass., April 8, 2014 /PRNewswire/
-- Decision Resources Group (DRG) finds that, for the treatment of
primary-progressive multiple sclerosis (PP-MS), surveyed U.S.
neurologists would be willing to accept a certain level of risk for a
therapy with proven efficacy on disability progression, likely owing to
the absence of approved therapies for this indication. This finding is
reflected by the fact that among hypothetical therapies assessed in
DRG's conjoint analysis tool, neurologists were most receptive to an
agent with the greatest efficacy improvement over the market's sales
leading therapy, Teva's Copaxone, but which was also associated with the
greatest risk of serious or life threatening side effects.
Other
key findings from the DecisionBase report entitled Chronic-Progressive
Multiple Sclerosis: Amid Substantial Unmet Need, What Magnitude of
Efficacy and Safety Do Neurologists and Payers Expect of a
First-To-Market Therapy for Primary-Progressive Multiple Sclerosis?:
Comments from Decision Resources Group Analyst Emma McFadden, Ph.D.:
About Decision Resources Group Decision
Resources Group offers best-in-class, high-value information and
insights on critical issues within the healthcare industry. Clients rely
on this analysis and data to make informed decisions. Find out more
atwww.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.
Source Story: The above story is based on materials provided by prnewswire Note: Materials may be edited due to content and
Labels: 100 MOST POPULAR, Copaxone VIDEO: Dr. Timothy Vollmer
There appears to be several different factors. One is genetics; the disease is more prevalent in people from Northern Europe. The second one is low Vitamin D levels early in life, and possibly in in-utero, increase the risk of MS subsequently," University of Colorado Doctor Tim Vollmer said. He says people in Colorado are normally diagnosed with low-levels of Vitamin D. Some experts believe Vitamin D levels may be low in the state because of Coloradan's use of sunscreen. Vollmer says new MS research and treatments are progressing at a remarkable rate. "The field Multiple Sclerosis is one of the most rapidly evolving fields of medicine right now. We have eight FDA therapies and three that are likely to be approved within the next year to 18 months. In the last year or so, we've developed a new blood test that would identify patients who are at risk of some of the serious side effects of the drugs. As a consequence, we can now identify people who are likely to do very well on a certain drug with a very low risk," Vollmer said. Read more » Labels: 100 MOST POPULAR, Dr. Timothy Vollmer, Tecfidera, Tysabri, Video Data Show Declining Use of Injectables as Oral Multiple Sclerosis Therapies Gain TractionUpdate
MSers STOPPING TYSABRI DO IT BECAUSE THEY ARE AT HIGH-RISK OF DEVELOPING PML....
BUT STOPPING TYSABRI LEADS TO REBOUND IN MS DISEASE ACTIVITY GILENYA APPEARS TO PREVENT THIS REBOUND IF IT'S STARTED WITHIN 4 WEEKS AFTER THE LAST TYSABRI INFUSION "The study below confirms what we already know; stopping Tysabri/natalizumab leads to rebound in MS disease activity. Switching to a DMT on a lower-tier of efficacy, i.e. interferon-beta or glatiramer acetate, or taking steroids does not prevent this rebound.
"Most MSers stopping Tysabri/natalizumab are doing it because they are at high-risk of developing PML. The major safety concern we have is so called carry-over PML; i.e. PML that presents in the first few months after starting fingolimod. I am aware of two cases of carry-over PML on fingolimod. Carry-over PML is a problem in that we rely on the immune response to clear you of PML; it takes about 6-8 weeks for fingolimod to wash-out of your system and during this time PML can cause devastating damage. Our practice, to prevent carry-over PML and rebound disease activity, is to do a MRI and lumbar puncture shortly after the last natalizumab infusion. If the spinal fluid analysis shows no JC virus DNA and the MRI shows no evidence of asymptomatic PML we start fingolimod within 4 weeks of the last natalizumab infusion. So far this practice seems to be working; touch wood we have had no cases of carry-over PML." SHARE THIS BY CLICKING TINY ENVELOPE BELOW Read more » Labels: 100 MOST POPULAR, 500 Best PML Stories & Studies, PML (Progressive Multifocal Leukoencephalopathy), Tysabri Friday Although
Parkinson’s disease and multiple sclerosis (MS) have little in common
clinically, besides being paralyzing neurological disorders, a report in
Nature reveals a drug for the former offers a new path for treatment of MS."We're excited about these results, and are now considering how to design an initial clinical trial," said chemist and senior author Dr. Luke Lairson of The Scripps Research Institute, who found that the Parkinson’s drug, benztropine (Cogentin), could repair a feature of MS that current drugs do not confront.
Read more » Labels: 100 MOST POPULAR |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||